Anti-(human Cd Antigen Cd37) (synthetic Human-mus Musculus Fragment Tru-016) Uses, Dosage, Side Effects and more
Anti-(human Cd Antigen Cd37) (synthetic Human-mus Musculus Fragment Tru-016) is under investigation in clinical trial NCT01188681 (Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia).
| Trade Name | Anti-(human Cd Antigen Cd37) (synthetic Human-mus Musculus Fragment Tru-016) |
| Generic | Otlertuzumab |
| Otlertuzumab Other Names | Immunoglobulin, anti-(human cd antigen cd37) (synthetic human-mus musculus fragment tru-016), dimer, Otlertuzumab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
